ArticleDiscover oncology2025
Identification of a novel ferroptosis-induced immunogenic cell death related signature based on a machine learning framework in colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multifunctional drug delivery of nanofibrous iron-polyphenolic nanochelates improved photothermal therapy against colorectal cancer via ferroptosis.Journal of materials science. Materials in medicine · 2026Article
- POSTNFrontiers in immunology · 2026Article
- The role of OTUD1-mediated deubiquitination in disease pathogenesis: from molecular mechanisms to clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFerroptosis and immunogenic cell death play vital roles in colorectal cancer (CRC). The interplay between ferroptosis and immunogenic cell death (F-ICD) represents a promising frontier in cancer therapy. However, few studies have explored the combined regulatory effects of F-ICD in CRC.
methodsIn current study, we identified F-ICD related genes based on analysis of single-cell transcriptomics level and developed F-ICD related signature using 101 machine learning algorithms and WGCNA analysis. Differential analysis between normal and tumor samples was performed using DESeq2 (|logFC|>1, p. adj < 0.05). The RSF algorithm was chosen for further analysis due to its strong predictive performance, making it a robust tool for our study. An external validation was performed to access the expression level of seven key F-ICD related genes.
resultsBy quantifying the expression levels of 44 genes related to F-ICD, we found that F-ICD activity was significantly elevated in NK cells, T cells, and some B cells. The module showed a significant correlation with the F-ICD score (r = 0.66). The predictive model had highly accurate AUCs in three datasets (0.99, 0.61, and 0.58 for the 3-years training sets), revealing the importance of F-ICD in different pathological stages and prognoses in CRC. Further results indicated that F-ICD was associated with pathways such as oxidative phosphorylation and NF-κB signaling. Patients with high F-ICD had significantly different mutation profiles and poorer prognoses.
conclusionThis study developed a novel signature integrating ferroptosis and immunogenic cell death, creating a valuable model for predicting prognosis and the tumor immune environment in CRC. Furthermore, seven key genes emerged as promising targets for further investigation and therapeutic intervention, highlighting their potential role in ferroptosis and immunogenic cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.